What You Should Know:
- Insilico Medicine, an NYC-based clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company raises $60 million in Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors.
- Insilico is also launching a new state-of-the-art robotics lab and fully robotic biological data factory. They have seen a string of successes thus far in 2022, including the
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
Buried Under Dirt or Under Debt: Can Patients Survive the Struggle of Getting Care?
New patients at a cancer center in Michigan receive a 79-page handbook when their treatments commence. The handbook includes needed advice on what to eat and the side effects of chemotherapy drugs. One double-sided page features information about how to navigate the financial aspects of cancer treatment, including who to contact for help with medical bills.
For Leslie Vreeland-Corpe of Michigan, one double-sided page couldn’t contain all the information she needed. After being diagnosed
Read More
Eli Lilly Partners with Yseop to Expedite Drug Approval Process
What You Should Know:
- Eli Lilly and Company partners with Yseop, an AI software company and pioneer in Natural Language Processing (NLP) to deploy Yseop’s world-class enterprise automation platform, Augmented Analyst, to accelerate bringing Lilly’s medicines to patients.
- Yseop’s platform uses Natural Language Generation (NLG) to augment human analysis with automated insights. With Yseop’s powerful AI automation technology, teams can shorten the time spent on specialist medical reports
Read More
Character Biosciences Raises $18M to Expand Precision Medicine Platform for Diseases of Aging
What You Should Know:
- Character Biosciences (“Character”), a precision medicine platform for diseases of aging raises $18M in a new funding round led by Innovation Endeavors, alongside leading life sciences investors Section 32 and Catalio Capital Management. Formerly known as Clover Therapeutics, the company’s data-driven approach integrates genomics, deep phenotyping and machine learning for target and biomarker discovery.
- The company will use the funding to advance the frontiers of
Read More
NVIDIA Launches AI Computing Platform for Medical Devices
What You Should Know:
- NVIDIA today introduced Clara Holoscan MGX, a platform for the medical device industry to develop and deploy real-time AI applications at the edge, specifically designed to meet required regulatory standards.
- Clara Holoscan MGX expands the Clara Holoscan platform to provide an all-in-one, medical-grade reference architecture, as well as long-term software support, to accelerate innovation in the medical device industry.
Clara Holoscan MGX Overview
As part
Read More
Benchling Acquires Overwatch Research to Accelerate Breakthroughs for Biopharma Companies
What You Should Know:
- Today, R&D Cloud pioneer Benchling announced it has acquired Overwatch Research to accelerate in vivo research.
- The acquisition will create the industry’s first comprehensive, cloud-native in vivo solution – a critical component of drug discovery and development – drastically accelerating the time it takes biopharma companies to bring products to market.
Digital Transforming R&D
In vivo studies are a critical component of drug discovery and
Read More
Sema4, BioSymetrics Partner to Advance Data-Driven Drug Discovery
What You Should Know:
- Today, Sema4, a leader in AI-driven clinical data intelligence, announced that they have partnered with BioSymetrics, to accelerate the advancement of drug discovery and new treatments for patients and pharmaceutical companies.
- Together the two will leverage Sema4’s Centrellis®, one of the largest and fastest-growing integrated health information platforms that includes approximately 12 million de-identified clinical records, and Elion, BioSymetrics’
Read More
PostEra Secures $24M, Forms $260M AI Lab Collaboration with Pfizer
What You Should Know:
- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients.
- PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform. True to its collaborative ethos, the company today also announced its
Read More
Protai Nabs $8M for AI-Powered Drug Discovery Platform
What You Should Know:
- Protai, a Tel Aviv, Israel-based AI-powered drug discovery startup, today announced its emergence from stealth, along with an $8 million seed financing round co-led by Grove Ventures and Pitango HealthTech.
- Protai empowers drug discovery with proteomics and artificial intelligence to unlock new layers of biological insights and to combat complex diseases.
Proteomics-based Platform for Faster and More Accurate Drug Discovery
Despite the significant
Read More
AWS and Pfizer Accelerate Drug Development and Clinical Manufacturing
What You Should Know:
Amazon Web Services (AWS) announced it is working with Pfizer to create innovative, cloud-based solutions to accelerate drug development and clinical manufacturing for testing in clinical trials.
Today, Amazon Web Services, Inc. (AWS) announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. The companies are
Read More
